FDA clears genetically engineered TIL therapy for solid tumour trials
Drug Discovery World
SEPTEMBER 3, 2024
Grit’s non-gene-engineered TIL programme, GT101, is currently in Phase II trials and is on track to file for Biologics License Application (BLA) in 2025, making it the leading TIL pipeline in China. The company raised over $60 million in a Series B financing round in September 2023 to support development of this programme.
Let's personalize your content